In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole–susceptible and azole–r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivero-Menendez, Olga, Soto-Debran, Juan Carlos, Cuenca-Estrella, Manuel, Alastruey-Izquierdo, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003840/
https://www.ncbi.nlm.nih.gov/pubmed/33804780
http://dx.doi.org/10.3390/jof7030232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003840/
https://www.ncbi.nlm.nih.gov/pubmed/33804780
http://dx.doi.org/10.3390/jof7030232

Ejemplares similares